Ovary rhabdomyosarcoma

Summary

Ovary rhabdomyosarcoma (MONDO:0002858) is a disease. A subtype of ovarian sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovary rhabdomyosarcoma
Mondo ID	MONDO:0002858
DOID	DOID:4059
NCIT	C5236
UMLS	C1335176
MedGen	233277
GARD	0023275
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	no

Also known as: ovarian rhabdomyosarcoma · ovary rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of ovary · rhabdomyosarcoma of ovary · rhabdomyosarcoma of the ovary

Disease family

This is a subtype of ovarian sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › ovarian cancer › ovarian sarcoma › ovary rhabdomyosarcoma

Related subtypes (3): ovarian angiosarcoma, ovary leiomyosarcoma, liposarcoma of the ovary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.